scholarly journals Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia

Blood ◽  
1997 ◽  
Vol 90 (11) ◽  
pp. 4628-4633 ◽  
Author(s):  
Anna Locasciulli ◽  
Marina Testa ◽  
Patrizia Pontisso ◽  
Luisa Benvegnù ◽  
Donatella Fraschini ◽  
...  

Abstract The aim of this study was to ascertain prevalence and natural history of hepatitis C virus (HCV) infection in a large cohort of patients cured of childhood leukemia who had been followed prospectively for liver disease for at least 10 years since chemotherapy withdrawal: 114 consecutive patients entered the study. Liver function tests and ultrasonography were used to assess presence of liver disease. Patients were tested for antibody to HCV and for serum HCV-RNA at the end of chemotherapy and at the end of follow-up. At chemotherapy withdrawal, 56 patients (49%) were HCV-RNA positive, often without detectable anti-HCV, and in these cases, transaminase levels were more elevated during (P = .08) and after (P = .04) chemotherapy compared with HCV-RNA negative cases. Patients were then followed-up 13 to 27 years (mean, 17) after chemotherapy withdrawal. During this period, 38 initially anti-HCV negative patients seroconverted to anti-HCV and 17 initially anti-HCV positive cases lost reactivity. Forty patients were persistently HCV-RNA positive in serum, while 16 initially viremic patients became HCV-RNA negative during follow-up. At the end of the observation period, a persistent transaminase elevation was detected only in four HCV-RNA positive and anti-HCV positive cases, while no patient developed signs or symptoms of decompensated liver disease. Thus, hepatitis C was a frequent finding in long-term survivors after chemotherapy. It was associated with an atypical serologic profile and did not cause severe liver impairment over a period of 13 to 27 years.

Blood ◽  
1997 ◽  
Vol 90 (11) ◽  
pp. 4628-4633 ◽  
Author(s):  
Anna Locasciulli ◽  
Marina Testa ◽  
Patrizia Pontisso ◽  
Luisa Benvegnù ◽  
Donatella Fraschini ◽  
...  

The aim of this study was to ascertain prevalence and natural history of hepatitis C virus (HCV) infection in a large cohort of patients cured of childhood leukemia who had been followed prospectively for liver disease for at least 10 years since chemotherapy withdrawal: 114 consecutive patients entered the study. Liver function tests and ultrasonography were used to assess presence of liver disease. Patients were tested for antibody to HCV and for serum HCV-RNA at the end of chemotherapy and at the end of follow-up. At chemotherapy withdrawal, 56 patients (49%) were HCV-RNA positive, often without detectable anti-HCV, and in these cases, transaminase levels were more elevated during (P = .08) and after (P = .04) chemotherapy compared with HCV-RNA negative cases. Patients were then followed-up 13 to 27 years (mean, 17) after chemotherapy withdrawal. During this period, 38 initially anti-HCV negative patients seroconverted to anti-HCV and 17 initially anti-HCV positive cases lost reactivity. Forty patients were persistently HCV-RNA positive in serum, while 16 initially viremic patients became HCV-RNA negative during follow-up. At the end of the observation period, a persistent transaminase elevation was detected only in four HCV-RNA positive and anti-HCV positive cases, while no patient developed signs or symptoms of decompensated liver disease. Thus, hepatitis C was a frequent finding in long-term survivors after chemotherapy. It was associated with an atypical serologic profile and did not cause severe liver impairment over a period of 13 to 27 years.


2003 ◽  
Vol 49 (6) ◽  
pp. 384-385 ◽  
Author(s):  
Azza El‐Sherbini ◽  
Wafaa Hassan ◽  
Mohamad Abdel‐Hamid ◽  
Ahmad Naeim

Blood ◽  
2000 ◽  
Vol 95 (10) ◽  
pp. 3065-3070 ◽  
Author(s):  
Donald K. Strickland ◽  
Caroline A. Riely ◽  
Christian C. Patrick ◽  
Dana Jones-Wallace ◽  
James M. Boyett ◽  
...  

Abstract Preliminary reports have suggested that survivors of childhood cancer and aplastic anemia who are infected with the hepatitis C virus (HCV) have a low risk for progression to significant liver disease. Among our surviving patients who were transfused between 1961 and March 1992, 77 (6.6% of surviving patients tested thus far) have evidence of HCV infection, whereas 4 surviving patients who were transfused after March 1992 are HCV-infected. One patient chronically infected with HCV died of liver failure, and 2 patients died of hepatocellular carcinoma. To characterize the risk for these and other complications, 65 patients are enrolled in a longitudinal study of HCV infection, of whom 58 (89.2%) had circulating HCV RNA at the time of protocol enrollment, with genotypes 1A and 1B most commonly isolated. Most enrolled patients have few or no symptoms, carry out normal activities, and have normal liver function. To date, 35 patients have undergone liver biopsy for abnormal liver function since the diagnosis of primary malignancy; central pathology review shows 28 (80%) have chronic active hepatitis, 25 (71%) have fibrosis, and 3 (9%) have cirrhosis. These preliminary data suggest that though most survivors of childhood cancer who are infected with HCV are clinically well, some are at risk for clinically significant liver disease. Identification of other HCV-infected patients and prospective monitoring of this cohort are ongoing to determine the risk for, and to identify factors associated with the progression of, liver disease.


2000 ◽  
Vol 7 (6) ◽  
pp. 420-427 ◽  
Author(s):  
H. E. Harris ◽  
M. E. Ramsay ◽  
J. Heptonstall ◽  
K. Soldan ◽  
K. P. Eldridge ◽  
...  

2010 ◽  
Vol 53 (2) ◽  
pp. 245-251 ◽  
Author(s):  
Ava John-Baptiste ◽  
Murray Krahn ◽  
Jenny Heathcote ◽  
Audery Laporte ◽  
George Tomlinson

Sign in / Sign up

Export Citation Format

Share Document